Tislelizumab plus Cetuximab and Irinotecan in Refractory Microsatellite Stable and RAS Wild-Type Metastatic Colorectal Cancer: A Single-Arm Phase II Study

Investigators conducted a proof-of-concept, single-arm, Phase II study of a combination treatment regimen including tislelizumab, cetuximab, and irinotecan in 33 patients with microsatellite stable and RAS wild-type metastatic colorectal cancer who were previously treated with ≥2 lines of therapy.